阿里健康首发中国目前唯一儿童药用级褪黑素曼乐静

Core Insights - The launch of Manlejing Melatonin Granules, the first pediatric melatonin medication in China, aims to address sleep difficulties in children aged 6-15 with neurodevelopmental disorders, marking a significant outcome of the strategic partnership between Ali Health and Dain Pharmaceutical established at the end of last year [1][2] Group 1: Product Launch and Collaboration - Manlejing Melatonin Granules is the only pediatric-grade melatonin in China, produced under strict GMP standards to ensure quality control from raw materials to finished products [2] - The product's active ingredient is identical to endogenous melatonin, with clinical studies indicating that it can significantly shorten sleep onset latency within two weeks and improve daytime behavioral issues in children with neurodevelopmental disorders [2][3] - The collaboration with Ali Health is aimed at leveraging its platform to connect with potential users and provide professional pharmaceutical services, ensuring safe medication use for families [2] Group 2: Market Need and Clinical Background - Approximately half of children with neurodevelopmental disorders in China experience insomnia, primarily characterized by difficulty falling asleep, which impacts their growth, behavior, and learning abilities [1] - Guidelines from the American Academy of Neurology (AAN) and the International Pediatric Sleep Association (IPSA) recommend melatonin as a first-line treatment for children with autism and ADHD who do not respond to behavioral interventions [1]